PharmaTher is developing its own Ketamine Hydrochloride Injection USP product as part of its plans to support the Company’s future Phase 3 clinical studies and its commercialization plans in the U.S. via an Abbreviated New Drug Application (ANDA) with the FDA for use in anesthesia and procedural sedation.
PharmaTher expects to form partnerships with research labs, ketamine clinics and pharmaceutical companies that are: seeking a secure supply of cGMP ketamine and ketamine products for current portfolios; exploring alternative dose forms for multiple existing indications; and requiring support to develop and eventually commercialize specific ketamine products for new indications. In addition, the Company will enter the market with KETARX targeting ketamine’s FDA approved label for anesthesia and procedural sedation
Connect With Us
PharmaTher Holdings Ltd. 82 Richmond Street East Toronto, Ontario Canada M5C 1P1